185 related articles for article (PubMed ID: 38312120)
21. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
Pan J; Shi Z; Lin D; Yang N; Meng F; Lin L; Jin Z; Zhou Q; Wu J; Zhang J; Li Y
Front Med; 2020 Feb; 14(1):43-50. PubMed ID: 31907860
[TBL] [Abstract][Full Text] [Related]
22. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial.
Ji CR; Liu J; Li YY; Qiao C; Qu JY; Hu JN; Lin MJ; Ji R; Li LX; Zuo XL; Li YQ
J Dig Dis; 2020 Oct; 21(10):549-557. PubMed ID: 32833285
[TBL] [Abstract][Full Text] [Related]
25. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole.
Marzio L; Coraggio D; Capodicasa S; Grossi L; Cappello G
Helicobacter; 2006 Aug; 11(4):237-42. PubMed ID: 16882326
[TBL] [Abstract][Full Text] [Related]
26. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?
Kutluk G; Tutar E; Bayrak A; Volkan B; Akyon Y; Celikel C; Ertem D
Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1202-8. PubMed ID: 25171023
[TBL] [Abstract][Full Text] [Related]
27. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?
Hung IF; Chan P; Leung S; Chan FS; Hsu A; But D; Seto WK; Wong SY; Chan CK; Gu Q; Tong TS; Cheung TK; Chu KM; Wong BC
Helicobacter; 2009 Dec; 14(6):505-11. PubMed ID: 19889067
[TBL] [Abstract][Full Text] [Related]
28. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
[TBL] [Abstract][Full Text] [Related]
29. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.
Antos D; Schneider-Brachert W; Bästlein E; Hänel C; Haferland C; Buchner M; Meier E; Trump F; Stolte M; Lehn N; Bayerdörffer E
Helicobacter; 2006 Feb; 11(1):39-45. PubMed ID: 16423088
[TBL] [Abstract][Full Text] [Related]
30. A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients with
Mokhtare M; Nikkhah M; Behnam B; Agah S; Bahardoust M; Masoodi M; Faghihi A
Indian J Pharmacol; 2020; 52(4):266-271. PubMed ID: 33078727
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance.
Park CS; Lee SM; Park CH; Koh HR; Jun CH; Park SY; Lee WS; Joo YE; Kim HS; Choi SK; Rew JS
Am J Gastroenterol; 2014 Oct; 109(10):1595-602. PubMed ID: 25091062
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial susceptibility testing before first-line treatment for
Cosme A; Montes M; Ibarra B; Tamayo E; Alonso H; Mendarte U; Lizasoan J; Herreros-Villanueva M; Bujanda L
World J Gastroenterol; 2017 May; 23(18):3367-3373. PubMed ID: 28566898
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
34. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
35. The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance.
Huang TH; Yang SC; Tai WC; Liang CM; Kuo CM; Yao CC; Wu CK; Kuo YH; Chou YP; Lee CH; Wu KL; Chuah SK
Biomed J; 2021 Dec; 44(6 Suppl 2):S275-S281. PubMed ID: 35292265
[TBL] [Abstract][Full Text] [Related]
36. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
Assem M; El Azab G; Rasheed MA; Abdelfatah M; Shastery M
Eur J Intern Med; 2010 Aug; 21(4):310-4. PubMed ID: 20603042
[TBL] [Abstract][Full Text] [Related]
38. The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing.
Li SY; Li J; Dong XH; Teng GG; Zhang W; Cheng H; Gao W; Dai Y; Zhang XH; Wang WH
Helicobacter; 2021 Aug; 26(4):e12804. PubMed ID: 33860967
[TBL] [Abstract][Full Text] [Related]
39. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.
Rakici H; Ayaz T; Akdogan RA; Bedir R
Digestion; 2014; 90(4):261-4. PubMed ID: 25547786
[TBL] [Abstract][Full Text] [Related]
40. Helicobacter pylori antimicrobial resistance in a pediatric population.
Silva GM; Silva HM; Nascimento J; Gonçalves JP; Pereira F; Lima R
Helicobacter; 2018 Oct; 23(5):e12528. PubMed ID: 30091503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
